BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21926937)

  • 1. Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
    Funamizu N; Kamata Y; Misawa T; Uwagawa T; Lacy CR; Yanaga K; Manome Y
    Pancreas; 2012 Jan; 41(1):107-13. PubMed ID: 21926937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
    Arumugam T; Ramachandran V; Fournier KF; Wang H; Marquis L; Abbruzzese JL; Gallick GE; Logsdon CD; McConkey DJ; Choi W
    Cancer Res; 2009 Jul; 69(14):5820-8. PubMed ID: 19584296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
    Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
    PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
    Hagmann W; Jesnowski R; Löhr JM
    Neoplasia; 2010 Sep; 12(9):740-7. PubMed ID: 20824050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.
    Jordheim LP; Guittet O; Lepoivre M; Galmarini CM; Dumontet C
    Mol Cancer Ther; 2005 Aug; 4(8):1268-76. PubMed ID: 16093443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.
    El Amrani M; Corfiotti F; Corvaisier M; Vasseur R; Fulbert M; Skrzypczyk C; Deshorgues AC; Gnemmi V; Tulasne D; Lahdaoui F; Vincent A; Pruvot FR; Van Seuningen I; Huet G; Truant S
    Mol Carcinog; 2019 Nov; 58(11):1985-1997. PubMed ID: 31373074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug resistance in breast cancer cells during epithelial-mesenchymal transition is modulated by breast cancer resistant protein.
    Chen WJ; Wang H; Tang Y; Liu CL; Li HL; Li WT
    Chin J Cancer; 2010 Feb; 29(2):151-7. PubMed ID: 20109342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
    Yao J; An Y; Wie JS; Ji ZL; Lu ZP; Wu JL; Jiang KR; Chen P; Xu ZK; Miao Y
    Swiss Med Wkly; 2011; 141():w13208. PubMed ID: 21630164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Binenbaum Y; Na'ara S; Gil Z
    Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
    Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
    J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
    Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
    PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
    Fan P; Liu L; Yin Y; Zhao Z; Zhang Y; Amponsah PS; Xiao X; Bauer N; Abukiwan A; Nwaeburu CC; Gladkich J; Gao C; Schemmer P; Gross W; Herr I
    Cancer Lett; 2016 Apr; 373(1):130-137. PubMed ID: 26828016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
    Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
    Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
    Jung CP; Motwani MV; Schwartz GK
    Clin Cancer Res; 2001 Aug; 7(8):2527-36. PubMed ID: 11489836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
    Tang ZY; Wu YL; Gao SL; Shen HW
    J Surg Res; 2008 Mar; 145(1):111-23. PubMed ID: 17714734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer stem-like cells enriched in Panc-1 spheres possess increased migration ability and resistance to gemcitabine.
    Yin T; Wei H; Gou S; Shi P; Yang Z; Zhao G; Wang C
    Int J Mol Sci; 2011; 12(3):1595-604. PubMed ID: 21673909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
    Skrypek N; Vasseur R; Vincent A; Duchêne B; Van Seuningen I; Jonckheere N
    Oncotarget; 2015 May; 6(13):10853-67. PubMed ID: 25890497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
    Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
    J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
    Zhou B; Su L; Hu S; Hu W; Yip ML; Wu J; Gaur S; Smith DL; Yuan YC; Synold TW; Horne D; Yen Y
    Cancer Res; 2013 Nov; 73(21):6484-93. PubMed ID: 24072748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression.
    Wang C; Zhang W; Fu M; Yang A; Huang H; Xie J
    Oncol Rep; 2015 Jan; 33(1):383-90. PubMed ID: 25394408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.